Literature DB >> 6799579

Measurement of the complement C3 breakdown product C3d by rocket immunoelectrophoresis.

B E Bourke, I K Moss, R N Maini.   

Abstract

A method is described for quantitative measurement of C3d in plasma and synovial fluid by the use of rocket immunoelectrophoresis after fractionation of the samples with 22% polyethylene glycol. This method has the advantage over radial immunodiffusion of being more sensitive (detecting C3d down to 3 mg/l) whilst proving equally reproducible. Investigations indicate that the collection of blood samples in EDTA prevents in vitro activation of C3 even after storage for up to 6 h at room temperature and up to 12 weeks at -70 degrees C. Elevated levels of C3d were found in a proportion of SLE and RA plasma samples and in synovial fluids from patients with inflammatory synovitis. It is suggested that C3 conversion in vivo may be assessed by measurement of C3d by the technique described, and when used in conjunction with measurements of complement components and immune complexes, offers a means of investigating complement catabolism by the classical and alternative pathways.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6799579     DOI: 10.1016/0022-1759(82)90214-9

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  12 in total

1.  Serum IgG levels and complement activity in hypogammaglobulinaemic patients under substitution therapy.

Authors:  A Plebani; L D Notarangelo; M Duse; A Avanzini; M Massa; A G Ugazio
Journal:  Clin Exp Immunol       Date:  1984-10       Impact factor: 4.330

2.  Burn wound sepsis may be promoted by a failure of local antibacterial host defenses.

Authors:  E A Deitch; R M Bridges; M Dobke; J C McDonald
Journal:  Ann Surg       Date:  1987-09       Impact factor: 12.969

3.  Measurement of the chemotactic complement fragment C5a in rheumatoid synovial fluids by radioimmunoassay: role of C5a in the acute inflammatory phase.

Authors:  P J Jose; I K Moss; R N Maini; T J Williams
Journal:  Ann Rheum Dis       Date:  1990-10       Impact factor: 19.103

4.  Differences in immunochemical characteristics of cryoglobulins in rheumatoid arthritis and systemic lupus erythematosus and their complement binding properties.

Authors:  C C Erhardt; P Mumford; R N Maini
Journal:  Ann Rheum Dis       Date:  1984-06       Impact factor: 19.103

5.  Complement split product C3d as an indicator of disease activity in systemic lupus erythematosus.

Authors:  E Röther; B Lang; R Coldewey; K Hartung; H H Peter
Journal:  Clin Rheumatol       Date:  1993-03       Impact factor: 2.980

6.  Reconstitution of the alternative pathway of complement by plasma infusions given to a patient with an SLE-like syndrome associated with a hereditary C3 dysfunction.

Authors:  B Nilsson; U R Nilsson; A Karlsson-Parra; G Sjölin-Forsberg; R Hällgren
Journal:  Ann Rheum Dis       Date:  1994-10       Impact factor: 19.103

7.  The complement fixing ability of putative circulating immune complexes in rheumatoid arthritis and its relationship to extra-articular disease.

Authors:  B E Bourke; I K Moss; P Mumford; A Horsfall; R N Maini
Journal:  Clin Exp Immunol       Date:  1982-06       Impact factor: 4.330

8.  Correlation of C3d fixing circulating immune complexes with disease activity and clinical parameters in patients with systemic lupus erythematosus.

Authors:  K Sekita; T Doi; E Muso; H Yoshida; K Kanatsu; Y Hamashima
Journal:  Clin Exp Immunol       Date:  1984-03       Impact factor: 4.330

9.  The use of C3d as a means of monitoring clinical activity in systemic lupus erythematosus and rheumatoid arthritis.

Authors:  W J Morrow; D J Williams; C Ferec; R Casburn-Budd; D A Isenberg; E Paice; M L Snaith; P Youinou; P Le Goff
Journal:  Ann Rheum Dis       Date:  1983-12       Impact factor: 19.103

10.  Detection and characterization of immunoconglutinins in patients with systemic lupus erythematosus (SLE): serial analysis in relation to disease course.

Authors:  B Nilsson; K N Ekdahl; A Sjöholm; U R Nilsson; G Sturfelt
Journal:  Clin Exp Immunol       Date:  1992-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.